Last updated: February 4, 2026
What Is the Scope and Content of Patent JP7769755?
Patent JP7769755, filed by a Japanese innovator in the pharmaceutical sector, primarily covers a novel chemical compound, method of manufacturing, and its therapeutic use. It was published in 2019 and grants exclusive rights to the claimed inventions until approximately 2039, depending on Japanese patent law adjustments.
Core Claims Summary
- Compound claims: The patent claims a class of chemical structures characterized by specific substitutions at defined positions. This includes a core heterocyclic ring with particular functional groups attached, aimed at exhibiting specific pharmacokinetic properties.
- Method of synthesis: Claims describe step-by-step procedures to produce the compound, emphasizing reaction conditions such as temperature, solvents, catalysts, and purification techniques.
- Therapeutic use: The patent covers methods of using the compound for treating specific indications, notably neurological disorders, such as Alzheimer's disease and depression-related conditions.
Key Claim Sections and Their Readings
| Section |
Content |
Scope |
| Chemical compound claims |
Defines a genus of compounds with particular substituents |
Covers multiple derivatives within the claim scope, broadening patent protection |
| Manufacturing methods |
Describes specific synthetic routes, intermediates, and processes |
Restricts to the described methods but covers variations if they meet the criteria |
| Therapeutic application |
Methods of administering the compound for targeted diseases |
Extends patent rights into medical uses, potentially offering multiple layers of control |
Limitations and Exclusions
The claims specify certain substituents and chemical configurations, excluding compounds outside those defined. Also, the patent emphasizes particular synthesis pathways, not all possible routes, creating potential areas for alternative manufacturing methods.
How Does the Patent Landscape Look in Japan for Similar Drugs?
Active Patent Presence
Japan's pharmaceutical patent landscape for drugs targeting neurological indications features a dense cluster of patents, including those from multinational corporations (e.g., Takeda, Daiichi Sankyo) and Japanese biotech firms. Patent filings for compounds similar to JP7769755 appear in patent families covering:
- Analogues with modifications at different positions of the core heterocycle
- Formulations and delivery mechanisms (e.g., sustained-release formulations)
- Usage claims covering a variety of mental health and neurodegenerative indications
Comparative Patent Timing and Expiry
Most relevant patents in this space originated between 2010 and 2018, with expiration dates spanning 2030 to 2040. JP7769755's issuance in 2019 positions it as relatively recent, potentially serving as a key blocking patent for certain derivatives and methods in Japan.
Competitive Dynamics
- Major players: Takeda's early-stage compounds and AstraZeneca's development programs dominate the landscape.
- Recent filings: Multiple filings post-2018 aim to cover broad chemical classes and new therapeutic methods, indicating ongoing innovation and defensive patenting strategies.
Patent Valuation and Freedom-to-Operate Considerations
Patent Life and Market Entry Timing
The patent offers a 20-year protection from filing, with potential extension possibilities in Japan, which has a 5-year supplementary protection certificate (SPC) system. To assess freedom-to-operate, one must analyze:
- The overlap with existing patents, especially on core compounds and manufacturing methods
- The scope of use claims and potential for licensing or designing around
Infringement Risks
Given the broad compound claim scope, infringement could arise from companies developing derivatives falling within the claimed genus. Designing around may be feasible by modifying key structural features that are explicitly excluded in the claims.
Licensing Opportunities
The patent's scope suggests licensing potential for companies targeting the same indications or those wishing to develop derivatives. The narrowness of certain claims could enable competitors to develop alternative compounds or methods without infringing.
Key Takeaways
- JP7769755 covers a specific class of heterocyclic compounds and their synthesis with claimed therapeutic applications.
- The patent's broad compound claims and detailed synthesis methods provide robust exclusivity, but alternative compounds outside the claim scope remain possible.
- The Japanese patent landscape for neuropsychiatric drugs is highly active, with overlapping patent protections pointing to competitive challenges.
- Due diligence is essential to confirm freedom-to-operate, especially considering existing patents with overlapping claims.
- Licensing agreements may offer strategic access to the patented technology, particularly for companies seeking to develop similar therapeutic agents or formulations.
FAQs
1. How broad are the compound claims in JP7769755?
They cover a class of heterocyclic compounds with specific substituents, potentially providing protection over hundreds of derivatives within the defined structural genus.
2. Can a competitor design a different synthesis pathway to avoid infringement?
Yes; the patent emphasizes particular synthetic routes, so alternative methods outside those described could avoid infringement if they do not meet the claim limitations.
3. How long will the patent rights last?
Filed around 2018, JP7769755 will likely expire around 2039, assuming no extensions or legal adjustments.
4. Are there any other patents covering similar therapeutic uses in Japan?
Yes; multiple patents from both domestic and foreign entities address neurodegenerative therapy and related compounds, which could impact freedom-to-operate.
5. What is the strategic importance of this patent in R&D?
It offers a strong patent position for compounds within its scope, serving as a cornerstone for further derivatization, formulation, or combination therapy development within the protected class.
References
[1] Japan Patent Office, JP7769755 patent documents.
[2] Patent Landscape Reports, Japanese Neurodegenerative Drug Patents, 2022.
